Why did Eris Lifesciences (ERIS) stock move recently?

On 7/23/2026, Eris Lifesciences moved -3.1% — Eris Lifesciences fell on a negative technical breakout after crossing below its 200-day moving average, as highlighted in today's Economic Times report on stocks triggering the signal. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Eris Lifesciences (ERIS) overvalued or fairly valued?

MarketChacha shows Eris Lifesciences's valuation in context — a forward P/E of about 22.5, a price-to-book of about 4.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Eris Lifesciences's revenue?

Eris Lifesciences reported revenue of ₹1,822 Cr for FY2026, with net profit of ₹244 Cr, per official filings.

What is the share price of Eris Lifesciences (ERIS)?

Eris Lifesciences last traded at ₹1,321.70 (+2.5% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Eris Lifesciences

ERIS · NSE · Pharma · India

Snapshot

TickerERIS

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersAhmedabad, India

Websitewww.eris.co.in

Filings tracked3

About Eris Lifesciences

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.

Who owns it

Promoters69.9%
Institutions22.4%
Public & other7.6%

56 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 2.9 points over the period — profitability is trending down.

Net margin trend22.7% → 19.8%

Margin has compressed by about 2.9 points over the period — profitability is trending down.

Growth qualityrev 17% · PAT 13%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹896 Cr

Next fiscal year

Rev ₹4,036 Cr · EPS 57.86

Est. earnings growth +32.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹3,129 Cr

Net margin

19.8%

Revenue CAGR (3y)

+22.9%

Profit CAGR (3y)

+17.5%

Net profit (FY2026)

₹620 Cr

Ask MarketChacha about ERIS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 23, 2026
Eris Lifesciences fell on a negative technical breakout after crossing below its 200-day moving average, as highlighted in today's Economic Times report on stocks triggering the signal.
source 1 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹3,129 Cr	₹620 Cr	19.8%
FY2025	₹2,894 Cr	₹352 Cr	12.2%
FY2024	₹2,009 Cr	₹392 Cr	19.5%
FY2023	₹1,685 Cr	₹382 Cr	22.7%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹873 Cr	₹142 Cr	16.3%
Q4 FY26	₹757 Cr	₹282 Cr	37.2%
Q3 FY26	₹807 Cr	₹100 Cr	12.3%
Q2 FY26	₹792 Cr	₹120 Cr	15.2%
Q1 FY26	₹773 Cr	₹118 Cr	15.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Board Meeting Outcome for Outcome For Board Meeting
As Attached
BSE8/31/2026
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015, - Availing Working Capital Term Loan From Axis Bank
as attached
BSE8/6/2026
Earnings Call Transcript
As Attached
BSE8/4/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.